STOCK TITAN
  1. Home
  2. Sec-filings
  3. LKFT
  4. [6-K] Lakefront Biotherapeutics NV Current Report (Foreign Issuer)

Lakefront Biotherapeutics buys €3.3M of shares

Lakefront Biotherapeutics repurchased 132,014 shares for about €3.28 million under its ongoing buyback program.

Filing Impact
(Neutral)
Filing Sentiment
(Neutral)
Form Type
6-K

Rhea-AI Filing Summary

Lakefront Biotherapeutics NV (LKFT) reports progress under its share repurchase program announced on June 9, 2026. Between August 31 and September 4, 2026, the company repurchased 132,014 ordinary shares through an independent financial intermediary for a total of €3,279,463.42, at an average price of €24.84 per share and within a price range of €24.44–€25.38.

As of market close on September 4, 2026, Lakefront holds 1,293,338 of its own ordinary shares. The company reiterates that plans to repurchase its ordinary shares involve forward-looking statements subject to the risks and uncertainties described in its SEC reports.

Positive

  • None.

Negative

  • None.
Shares repurchased 132,014 shares Total repurchased between August 31 and September 4, 2026
Average repurchase price €24.84 per share Weighted average price over the August 31–September 4, 2026 period
Total repurchase amount €3,279,463.42 Cash spent on repurchases August 31–September 4, 2026
Repurchase price range €24.44–€25.38 per share Lowest and highest prices paid during the reported period
Treasury shares held 1,293,338 shares Own shares held as of market close on September 4, 2026
Announcement date of repurchase program June 9, 2026 Date the ongoing share repurchase program was announced
repurchase program financial
"Within the framework of the repurchase program announced on June 9, 2026"
A repurchase program is when a company buys back its own shares from the open market. This reduces the total number of shares available, which can increase the value of each remaining share and signal confidence in the company's future. For investors, it often suggests that the company believes its stock is undervalued and can be a sign of financial strength.
discretionary mandate financial
"it has repurchased 132,014 Lakefront shares via a discretionary mandate"
independent financial intermediary financial
"via a discretionary mandate to an independent financial intermediary"
forward-looking statements regulatory
"This press release contains forward-looking statements within the meaning"
Forward-looking statements are predictions or plans that companies share about what they expect to happen in the future, like estimating sales or profits. They matter because they help investors understand a company's outlook, but since they are based on guesses and assumptions, they can sometimes be wrong.
BCMAxCD3 T‑cell engager medical
"anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager"

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What share repurchases did Lakefront Biotherapeutics (LKFT) report for late August and early September 2026?
Lakefront repurchased 132,014 ordinary shares between August 31 and September 4, 2026, under its existing buyback program, spending €3,279,463.42 at an average price of €24.84 per share.

What is the price range of Lakefront Biotherapeutics’ (LKFT) recent share buybacks?
During the August 31–September 4, 2026 period, Lakefront’s repurchases occurred within a price range of €24.44 to €25.38 per share, with an average price of €24.84 per share.

How many treasury shares does Lakefront Biotherapeutics (LKFT) currently hold?
As of market close on September 4, 2026, Lakefront holds 1,293,338 of its own ordinary shares as treasury shares.

Through what mechanism did Lakefront Biotherapeutics (LKFT) conduct the recent repurchases?
Lakefront conducted the repurchases via a discretionary mandate to an independent financial intermediary as part of its share repurchase program announced on June 9, 2026.

What forward-looking caution does Lakefront Biotherapeutics (LKFT) give about its repurchase plans?
Lakefront states that its plans to repurchase ordinary shares are forward-looking statements subject to risks and uncertainties described in its SEC filings, and may differ from actual future results or actions.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →
See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google
Add on Google
 

UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER PURSUANT TO RULE 13a-16 OR 15d-16 UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of September 2026

Commission File Number: 001-37384

Lakefront Biotherapeutics
(Translation of registrant's name into English)

Schaliënhoevedreef 20T, 2800 Mechelen, Belgium
(Address of principal executive office)

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F.
Form 20-F [ X ]      Form 40-F [   ]

The information contained in this Report on Form 6-K, including Exhibit 99.1, is hereby incorporated by reference into the Company's Registration Statements on Form S-8 (File Nos. 333-204567, 333-208697, 333-211834, 333-215783, 333- 218160, 333-225263, 333-231765, 333-249416, 333-260500, 333-268756, 333-275886, 333-283361, and 333-292050).

On September 8, 2026, the Registrant issued a press release, a copy of which is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Exhibit 99.1. Press release dated September 8, 2026

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, thereunto duly authorized.

      Lakefront Biotherapeutics    
  (Registrant)
   
  
Date: September 8, 2026     /s/ Ying Deng    
  Ying Deng
  Authorized Officer
  

EXHIBIT 99.1

Acquisition of Own Shares

Mechelen, Belgium; 08 September 2026, 22.01 CET; regulated information

Within the framework of the repurchase program announced on June 9, 2026, Lakefront Biotherapeutics NV (Euronext & NASDAQ: LKFT) ("Lakefront") announces that between August 31, 2026 and September 04, 2026 it has repurchased 132,014 Lakefront shares via a discretionary mandate to an independent financial intermediary, as follows:

Date of purchase Market/MTF Number of shares Average price paid (€) Total (€) Lowest price paid (€) Highest price paid (€)
31/08/2026 XAMS 24,235 24.73 599,331.55 24.44 24.96
31/08/2026 AQEU 731 24.68 18,038.08 24.60 24.88
31/08/2026 CEUX 3,385 24.67 83,493.39 24.56 24.88
31/08/2026 TQEX 1,779 24.76 44,056.76 24.56 24.88
01/09/2026 XAMS 21,260 24.61 523,180.96 24.46 24.74
01/09/2026 AQEU 380 24.57 9,338.31 24.54 24.70
01/09/2026 CEUX 974 24.56 23,919.39 24.52 24.68
01/09/2026 TQEX 1 24.54 24.54 24.54 24.54
02/09/2026 XAMS 20,515 24.97 512,310.84 24.70 25.38
02/09/2026 AQEU 849 25.03 21,250.89 24.82 25.16
02/09/2026 CEUX 527 24.93 13,136.00 24.82 24.98
02/09/2026 TQEX 138 25.05 3,456.58 24.84 25.16
03/09/2026 XAMS 25,909 25.03 648,592.95 24.86 25.16
03/09/2026 AQEU 192 25.04 4,807.68 25.04 25.04
03/09/2026 CEUX 2,456 25.17 61,819.24 25.04 25.18
04/09/2026 XAMS 24,704 24.85 613,795.58 24.56 25.10
04/09/2026 AQEU 883 24.90 21,989.44 24.76 24.92
04/09/2026 CEUX 3,048 24.85 75,732.74 24.64 25.12
04/09/2026 TQEX 48 24.76 1,188.48 24.76 24.76
Total   132,014 24.84 3,279,463.42 24.44 25.38

As of market close on 04 September 2026, Lakefront holds 1,293,338 of its own ordinary shares.

About Lakefront Biotherapeutics
Lakefront Biotherapeutics is a biotechnology company dedicated to building a differentiated pipeline of medicines for patients with serious diseases in areas of high unmet need. The Company has established a clinical‑stage portfolio in immunology and inflammation, anchored by gamgertamig, a potential first‑in‑class and best-in-class BCMAxCD3 T‑cell engager for autoimmune diseases. Backed by deep deal‑making expertise, operational flexibility, and a strong capital position, Lakefront identifies, acquires, and advances high‑quality assets with clear potential to deliver meaningful patient impact and long‑term shareholder value. For more information, visit https://www.lakefrontbio.com or follow us on LinkedIn or X.

For further information, contact Lakefront Biotherapeutics:
Investor Relations
Sherri Spear
+1 412 522 6418
sherri.spear@lakefrontbio.com

Forward-looking statements
This press release contains forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, all of which involve certain risks and uncertainties. These statements are often, but are not always, made through the use of words or phrases such as “believe,” “anticipate,” “expect,” “intend,” “plan,” “seek,” “upcoming,” “future,” “estimate,” “may,” “will,” “could,” “would,” “potential,” “forward,” “goal,” “next,” “continue,” “should,” “encouraging,” “aim,” “progress,” “remain,” “explore,” and “further,” as well as similar expressions. These statements include, but are not limited to, statements regarding Lakefront’s plans to repurchase its ordinary shares. Lakefront cautions the reader that forward-looking statements are based on our management’s current expectations and beliefs and are not guarantees of future performance. Forward-looking statements may involve known and unknown risks, uncertainties and other factors which might cause actual events, financial condition and liquidity, performance, or achievements, or the industry in which we operate, to be materially different from any historic or future results, financial conditions, performance or achievements expressed or implied by such forward-looking statements. In addition, even if our results, performance, financial condition and liquidity, and the development of the industry in which Lakefront operates are consistent with such forward-looking statements, they may not be predictive of results or developments in future periods. Such risks include, but are not limited to, those risks and uncertainties that can be found in our filings and reports with the Securities and Exchange Commission (“SEC”), including in our most recent annual report on Form 20-F filed with the SEC and our subsequent filings and reports filed with the SEC. Given these risks and uncertainties, the reader is advised not to place any undue reliance on such forward-looking statements. In addition, even if the result of our operations, financial condition and liquidity, or the industry in which we operate, are consistent with such forward-looking statements, they may not be predictive of results, performance or achievements in future periods. These forward-looking statements speak only as of the date of publication of this release. We expressly disclaim any obligation to update any such forward-looking statements in this release to reflect any change in our expectations or any change in events, conditions or circumstances, unless specifically required by law or regulation.

Source: View Original Filing on SEC EDGAR

Filing Exhibits & Attachments

1 document

Press Releases

Keep reading

More on LKFT

Trending in the feed

Open the live feed